| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 454.98 | 6.3% |
| Total Income | 455.56 | 6.2% |
| Expenditure | 443.01 | 5.5% |
| PBT | 12.55 | 44.8% |
| Net Profit | 7.84 | 40.0% |
| OPM | -4.56% | 1.84pp |
| NPM | 1.72% | 0.41pp |
| EPS | 0.35 | 40.0% |
NECTAR LIFESCIENCES LTD. Reports Consistent Growth in Q3 FY25 with Significant Increase in Profitability
31 Jan 2025 · 31 Jan 2025, 11:18 pm
Summary
NECTAR LIFESCIENCES LTD. has reported consistent growth in its financial performance for Q3 FY25. The company's Revenue from Operations was 4,543.34 million, an increase from 4,521.65 million in Q3 FY24 and an improvement from 4,278.85 million in Q2 FY25. EBITDA stood at 452.83 million, reflecting an increase from 426.71 million in Q3 FY24 and 440.23 million in Q2 FY25. Profit Before Tax (PBT) for Q3 FY25 was 125.48 million, a significant increase from 24.57 million in Q3 FY24 and 86.66 million in Q2 FY25. Profit After Tax (PAT) came in at 78.40 million, marking a substantial growth from 15.67 million in Q3 FY24 and 55.99 million in Q2 FY25. The company is strategically positioning for increased market penetration and focusing on expanding presence in higher-margin APl and formulations export markets.
Key Highlights
- 1
Revenue from Operations for Q3 FY25 was 4,543.34 million, a marginal increase from 4,521.65 million in Q3 FY24 and an improvement from 4,278.85 million in Q2 FY25.
- 2
EBITDA stood at 452.83 million, reflecting an increase from 426.71 million in Q3 FY24 and 440.23 million in Q2 FY25.
- 3
Profit Before Tax (PBT) for Q3 FY25 was 125.48 million, a significant increase from 24.57 million in Q3 FY24 and 86.66 million in Q2 FY25.
- 4
Profit After Tax (PAT) came in at 78.40 million, marking a substantial growth from 15.67 million in Q3 FY24 and 55.99 million in Q2 FY25.
- 5
The management plans incremental capital expenditure to strengthen production capabilities and aims to scale sales from the formulations business to ¥600 crore+ by FY28.
Management Comments
NECTAR LIFESCIENCES LTD. Management
We are strategically positioning ourselves for increased market penetration, focusing on expanding presence in higher-margin API and formulations export markets to drive profitability. The company is actively pursuing debt reduction initiatives, which will lower interest costs and enhance financial health. To meet growing demand, the management plans incremental capital expenditure to strengthen production capabilities. Additionally, ongoing cost optimization measures and process efficiencies are expected to sustain profitability and drive shareholder value. Management anticipates a 100-150 bps expansion in EBITDA margins annually, supported by a rising share of API exports and formulations. For FY25, EBITDA is projected at 175-185 crore. Revenue growth of 7-10% is expected in FY26, leading to an estimated EBITDA of %240-260 crore. The management is focused on the formulations business and aims to scale sales from this business to 600 crore+ by FY28. By the end of FY26, long-term debt is expected to be fully repaid, significantly reducing interest costs and further enhancing profitability at the PAT level.
Informational and educational content only. Not investment advice.